Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Treace Medical Concepts, Inc. is a U.S.-based medical device company focused on the development and commercialization of surgical solutions for the treatment of hallux valgus, commonly known as bunion deformities. The company operates within the orthopedic medical device industry, specifically serving the foot and ankle surgical market. Its core customers are orthopedic surgeons, podiatrists, and ambulatory surgery centers seeking reproducible, anatomically aligned surgical outcomes.
The company’s primary revenue driver is its proprietary Lapiplasty® 3D Bunion Correction™ System, which is designed to correct all three planes of the bunion deformity and stabilize the affected joint. Treace Medical Concepts positions itself as a category creator in bunion correction by emphasizing procedural standardization, instrumented surgery, and surgeon education. The company was founded in 2013 by John T. Treace and completed its initial public offering in 2021, using the proceeds to expand commercialization, clinical education, and product development.
Business Operations
Treace Medical Concepts operates as a single-reportable-segment company focused on the commercialization of its bunion correction platform, with revenues generated primarily through the sale of surgical instruments, implants, and related procedure-specific products. The company’s portfolio includes the Lapiplasty® System, Adductoplasty™, and complementary fixation and instrumentation solutions used during foot and ankle procedures.
Operations are primarily domestic, with the majority of revenue generated in the United States through a direct sales force that supports surgeon training, case coverage, and hospital relationships. International revenue is generated on a limited basis through distribution arrangements in select markets. The company maintains control over product design, clinical education programs, and surgeon training infrastructure, which it considers integral to driving adoption and procedural consistency.
Strategic Position & Investments
Treace Medical Concepts’ strategy centers on expanding adoption of its bunion correction platform by increasing surgeon penetration, broadening procedural indications, and enhancing its instrumented surgery ecosystem. Growth initiatives emphasize clinical evidence generation, continued innovation around fixation and instrumentation, and expansion of surgeon education programs designed to reduce procedural variability.
The company has historically prioritized internal research and development over large-scale acquisitions, with investments focused on next-generation implants, workflow-enhancing technologies, and data-driven surgical planning tools. Emerging areas of focus include adjacent midfoot procedures and refinements to post-operative stabilization techniques. Public disclosures indicate no material reliance on joint ventures, with strategic partnerships primarily limited to distribution and clinical education collaborations.
Geographic Footprint
Treace Medical Concepts is headquartered in the United States, with its principal executive offices in Florida. The company’s commercial footprint is heavily concentrated in North America, where it maintains a direct sales and clinical support organization covering major metropolitan and regional healthcare markets.
Internationally, Treace Medical Concepts has a limited but growing presence across parts of Europe, Asia-Pacific, and Latin America, primarily through third-party distributors. While international operations currently represent a smaller portion of total revenue, management has identified selective international expansion as a longer-term growth opportunity, subject to regulatory approvals and market readiness.
Leadership & Governance
Treace Medical Concepts was founded by John T. Treace, whose clinical background and industry experience shaped the company’s focus on procedural standardization and surgeon-centric design. The leadership team emphasizes disciplined growth, clinical validation, and long-term category leadership in foot and ankle surgery.
Key executives include:
- John T. Treace – Founder, President, and Chief Executive Officer
- John H. Appleby – Chief Financial Officer
- Adam E. Lindsay, DPM – Chief Medical Officer
The board and executive team articulate a governance philosophy centered on evidence-based innovation, compliance with regulatory standards, and alignment with long-term shareholder value creation.